However, with the second approach, we found that neither type II IS nor MS-DMD allowed controlling clinical activity or cumulative disability, as previously described for MS-DMD both in MOG-Ab-positive patients and NMOSD [17, 37–39]. The gene discussed is MOG; the disease is Duchenne muscular dystrophy.